Pieris Pharmaceuticals, Inc.
NASDAQ:PIRS
13.6 (USD) • At close December 13, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Pieris Pharmaceuticals, Inc. |
Symbool | PIRS |
Munteenheid | USD |
Prijs | 13.6 |
Beurswaarde | 17,955,264 |
Dividendpercentage | 0% |
52-weken bereik | 6.2 - 22.32 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Stephen S. Yoder J.D. |
Website | https://www.pieris.com |
An error occurred while fetching data.
Over Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)